XML 45 R35.htm IDEA: XBRL DOCUMENT v3.8.0.1
Collaboration and License Agreements (Details)
$ in Thousands, € in Millions
1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended
Nov. 30, 2017
USD ($)
Oct. 31, 2017
USD ($)
Nov. 30, 2015
USD ($)
Mar. 31, 2015
USD ($)
Oct. 31, 2014
USD ($)
Oct. 31, 2014
EUR (€)
Mar. 31, 2018
USD ($)
Sep. 30, 2017
USD ($)
Mar. 31, 2017
USD ($)
Sep. 30, 2016
USD ($)
Sep. 30, 2017
USD ($)
Sep. 30, 2016
USD ($)
Dec. 31, 2015
USD ($)
Dec. 31, 2014
USD ($)
Collaboration and License Agreements [Abstract]                            
Sanofi Upfront Payment     $ 300,000                      
Sanofi Development Milestones     110,000                      
Sanofi Regulatory Milestones     220,000                      
Sanofi Outcomes Study Milestone     100,000                      
Sanofi Sales Milestone Payments     990,000                      
Sanofi Commercialization Costs Funded by Lexicon Maximum Amount     100,000                      
Sanofi Revenue Allocated to License Deliverable     126,800                      
Sanofi Revenue Allocated to Development Deliverable     113,800                      
Sanofi Revenue Allocated to Funding Deliverable     $ 59,400                      
Sanofi Revenue Recognized             $ 19,100   $ 17,000          
Ipsen Total Payments             43,700              
Ipsen Maximum Regulatory And Commercial Milestones         $ 13,000                  
Ipsen Maximum Sales Milestones | €           € 72                
Ipsen Total Upfront Payments       $ 24,500                    
Ipsen Milestone Payment                   $ 6,400 $ 5,100 $ 6,400    
Ipsen Milestone Payment Received $ 3,840 $ 3,840           $ 5,100            
Ipsen Revenue Allocated to License Deliverable                         $ 1,400 $ 21,200
Ipsen Revenue Allocated to Development Deliverable         1,700                  
Ipsen Revenue Allocated to Committee Deliverable         $ 100                  
Ipsen Revenue Recognized             $ 300   $ 500